DeepSummary
The podcast discusses the potential approval of MDMA-assisted therapy for post-traumatic stress disorder (PTSD) by the FDA in August. It highlights the promising results from clinical trials, where around 71% of participants no longer met the diagnostic criteria for PTSD after the treatment. However, a recent report has raised concerns about the validity of the trial data, accusing researchers of potential bias and overlooking adverse events.
The report, published by the Institute for Clinical and Economic Review, criticized the study design and suggested that strong beliefs among therapists and patients could have influenced the results. It cited anonymous sources and a podcast that presented video evidence of inappropriate behavior by therapists during sessions. The nonprofit organization MAPS, which pioneered the research, and the drug company Lycos Therapeutics have defended the integrity of the trials.
The episode explores the perspectives of researchers involved in the trials, who reject claims of bias and emphasize the rigorous protocols followed. A public hearing is scheduled before the FDA's decision, allowing for further discussion and comments from various stakeholders. The potential approval of MDMA-assisted therapy for PTSD represents a milestone for the psychedelic movement and could provide a new treatment option for those suffering from the disorder.
Key Episodes Takeaways
- The FDA is expected to decide in August whether to approve MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD).
- Clinical trials have shown promising results, with around 71% of participants no longer meeting the diagnostic criteria for PTSD after the treatment.
- A recent report by the Institute for Clinical and Economic Review has raised concerns about the validity of the trial data, accusing researchers of potential bias and overlooking adverse events.
- The nonprofit organization MAPS and the drug company Lycos Therapeutics, which sponsored the trials, have defended the integrity of the research and rejected claims of misconduct.
- A public hearing will be held before the FDA's decision, allowing for further discussion and comments from various stakeholders.
- The potential approval of MDMA-assisted therapy for PTSD represents a milestone for the psychedelic movement and could provide a new treatment option for those suffering from the disorder.
- Concerns have been raised about the potential risks associated with the approval of MDMA-assisted therapy if the research is not conducted properly.
- The FDA's decision will have significant implications for the future of psychedelic-assisted therapy in mental health care.
Top Episodes Quotes
- “I didn't feel any pressure from the sponsor to come up with anything different than what the data was providing. I didn't feel that at all and wouldn't have continued to work with them if I had felt that.“ by Jennifer Mitchell
- “There is a lot of potential for MDMA, but I think that the research has to be done properly or else the rollout could harm a lot of people potentially.“ by Nishe Devineau
- “You have a group of people who are very upset about how these trials went. We couldn't tell, even though we talked with people, where this happened, whether that represents a tiny fraction of bad events or a number of bad events large enough to have rendered the trial just not believable.“ by David Rind
Entities
Company
Organization
Product
Person
Concept
Episode Information
Short Wave
NPR
6/3/24
NPR science reporter Will Stone talks to host Emily Kwong about the clinical trials on MDMA-assisted therapy research and a recent report questioning the validity of the results.
Read Will's full story here.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy